-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Inspira Technologies Granted Patent By The Israeli Patent Office For Key Safety Component For The INSPIRATM ART System
Inspira Technologies Granted Patent By The Israeli Patent Office For Key Safety Component For The INSPIRATM ART System
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that the Israeli Patent Office (ILPO) granted a patent for a key safety component of the INSPIRATM ART system.
The component is to be located on the patient's neck and is designed to secure a neck cannula from moving or dislodging. Cannula movement can occur during a change of a patient's posture in bed, during physiotherapy treatment, while an awake patient is taken by the medical staff out of bed for a short walk and/or during transportation within and between hospitals.
"We believe that the grant of this patent is another validation of our innovation and supports our core mission for the INSPIRA ART system – to reduce the dependency on invasive mechanical ventilation and improve patient safety and outcomes," stated Inspira's CEO, Dagi Ben-Noon. "This patent is part of the Company's portfolio of patents that are at various phases of the filing process and which we expect to see progress to grant status."
The ILPO is a certified International Searching and Examining Authority (ISA), appointed by the World Intellectual Property Organization (WIPO), and a party to the PCT-PPH Program, an international initiative amongst 30+ national patent offices to promote work-sharing and enable accelerated patent applicant processing. The Company plans to file for patent coverage in additional countries.
Enhances Usability and Medical Value of INSPIRA ART System
The newly patented technology shall be a key component of the INSPIRA ART system, a potential new mode of acute respiratory care under development, designed to minimize the need for invasive mechanical ventilation allowing the patient to remain awake and maintain spontaneous breathing
The component will be utilized during INSPIRA ART treatment with awake patients, potentially allowing them to be mobile with reduced risk of cannula movement and subsequent bleeding. The Company believes that such improvement in patient safety and mobilization increases patient benefit and enhances the INSPIRA ART system's usability and comprehensive medical value to both patient and medical staff, which may accelerate market adoption.
Potential Use For ECMO
While the component was initially intended to be a part of the INSPIRA ART system, the Company will also explore the potential early release of the component for the Extracorporeal Membrane Oxygenation (ECMO) device market. The current ECMO market size (including devices) is estimated at $531 million per annum, with approximately 35,000 ECMO procedures performed each year.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that the Israeli Patent Office (ILPO) granted a patent for a key safety component of the INSPIRATM ART system.
Inspira Technologies Oxy B.H.N.Ltd.具有開創性的呼吸支持技術公司(納斯達克:IINN)(納斯達克:IINNW)(以下簡稱“公司”或“Inspira Technologies”)今天宣佈,以色列專利局(ILPO)為INSPIRATM ART系統的一個關鍵安全部件授予了一項專利。
The component is to be located on the patient's neck and is designed to secure a neck cannula from moving or dislodging. Cannula movement can occur during a change of a patient's posture in bed, during physiotherapy treatment, while an awake patient is taken by the medical staff out of bed for a short walk and/or during transportation within and between hospitals.
該組件將安裝在患者的頸部,旨在確保頸部插管不會移動或移位。當病人在牀上的姿勢改變時,在物理治療期間,當醒着的病人被醫務人員從牀上抱起來散步和/或在醫院內和醫院之間運送時,插管可能會發生移動。
"We believe that the grant of this patent is another validation of our innovation and supports our core mission for the INSPIRA ART system – to reduce the dependency on invasive mechanical ventilation and improve patient safety and outcomes," stated Inspira's CEO, Dagi Ben-Noon. "This patent is part of the Company's portfolio of patents that are at various phases of the filing process and which we expect to see progress to grant status."
Inspira首席執行官Dagi Ben-Noon表示:“我們認為,授予這項專利是對我們創新的又一次驗證,並支持我們對INSPIRA ART系統的核心使命--減少對有創機械通氣的依賴,改善患者的安全和預後。”這項專利是該公司專利組合的一部分,這些專利正處於申請過程的不同階段,我們預計這些專利將在授予地位方面取得進展。“
The ILPO is a certified International Searching and Examining Authority (ISA), appointed by the World Intellectual Property Organization (WIPO), and a party to the PCT-PPH Program, an international initiative amongst 30+ national patent offices to promote work-sharing and enable accelerated patent applicant processing. The Company plans to file for patent coverage in additional countries.
ILPO是由世界知識產權組織(WIPO)任命的經認證的國際檢索和審查機構(ISA),也是PCT-PPH計劃的成員,PCT-PPH計劃是30多個國家專利局之間的一項國際倡議,旨在促進工作共享和加快專利申請人的處理。該公司計劃在更多國家申請專利。
Enhances Usability and Medical Value of INSPIRA ART System
增強INSPIRA ART系統的可用性和醫療價值
The newly patented technology shall be a key component of the INSPIRA ART system, a potential new mode of acute respiratory care under development, designed to minimize the need for invasive mechanical ventilation allowing the patient to remain awake and maintain spontaneous breathing
這項新的專利技術將是INSPIRA ART系統的關鍵組成部分,INSPIRA ART系統是一種正在開發的潛在的急性呼吸護理新模式,旨在最大限度地減少對允許患者保持清醒和自主呼吸的有創機械通氣的需求
The component will be utilized during INSPIRA ART treatment with awake patients, potentially allowing them to be mobile with reduced risk of cannula movement and subsequent bleeding. The Company believes that such improvement in patient safety and mobilization increases patient benefit and enhances the INSPIRA ART system's usability and comprehensive medical value to both patient and medical staff, which may accelerate market adoption.
該組件將在對清醒患者進行INSPIRA ART治療期間使用,有可能使他們能夠活動,從而降低插管移動和隨後出血的風險。該公司認為,在患者安全和動員方面的這種改進增加了患者的利益,並提高了INSPIRA ART系統的可用性和對患者和醫務人員的綜合醫療價值,這可能會加速市場的採用。
Potential Use For ECMO
ECMO的潛在用途
While the component was initially intended to be a part of the INSPIRA ART system, the Company will also explore the potential early release of the component for the Extracorporeal Membrane Oxygenation (ECMO) device market. The current ECMO market size (including devices) is estimated at $531 million per annum, with approximately 35,000 ECMO procedures performed each year.
雖然該組件最初的目的是作為INSPIRA ART系統的一部分,但該公司還將探索該組件在體外膜氧合(ECMO)設備市場上提前發佈的可能性。目前ECMO的市場規模(包括設備)估計為每年5.31億美元,每年大約進行35,000次ECMO手術。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧